Vanguard Capital Management
LAB icon

Vanguard Capital Management’s Standard BioTools LAB Stock Holding History

Vanguard Capital Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.1M Sell
12,252,998
-563,072
-4% -$532K ﹤0.01% 2809
2026
Q1 		$11.8M Buy
+12,816,070
New +$15.5M ﹤0.01% 2638

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management's LAB Position: Q2 2026 in Review

Vanguard Capital Management reduced its Standard BioTools (LAB) stake by 4.4% in Q2 2026, selling an estimated $532K and leaving 12,252,998 shares worth $10.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2809.

Vanguard Capital Management first reported a position in LAB in Q1 2026 and has held it in 2 quarters since. The position peaked at $11.8M in Q1 2026. 143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • Vanguard Capital Management held 12,252,998 shares of Standard BioTools worth $10.1M as of Q2 2026.
  • Vanguard Capital Management sold 563,072 Standard BioTools shares in Q2 2026, an estimated $532K.
  • Standard BioTools made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2809 holding.
  • Vanguard Capital Management first reported a position in Standard BioTools in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Standard BioTools position peaked at $11.8M in Q1 2026.
  • 143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.